Cost-effectiveness of Olaparib plus Bevacizumab versus Bevacizumab in the maintenance of patients with HRD plus advanced ovarian cancer after response to first-line platinum-based chemotherapy in Spain.-MedSci.cn

Cost-effectiveness of Olaparib plus Bevacizumab versus Bevacizumab in the maintenance of patients with HRD plus advanced ovarian cancer after response to first-line platinum-based chemotherapy in Spain.

Perez-Fidalgo, JA; Lleti, ACC; Manso, L; Herraez, AC; Bosch, PV; Gari, C; Marti, MP; Gomez, SC